Widespread US shift from prescription to OTC lies in pharma’s hands
While the FDA maintains the legal right to make prescription meds OTC, legal expert Heidi Gertner believes that this wider shift depends on pharma’s engagement.
Regulation
Rare disease developers applaud clarity in FDA guidance
FDA’s commissioner vouchers prompt questions about award process
Medical bodies sound alarm over US hepatitis B vaccine vote
FDA appoints Tracy Beth Høeg as fifth CDER head this year
FDA inspection reveals critical supply chain vulnerabilities
EuropaBio calls for “bold approach to investment” amid EU Biotech Act
FDA’s revolving door reveals Pazdur as new CDER head
